Sandbox

Probando

<R output="html" iframe="width:100%;height:250px;"> prob=0.15; nmin=1; nmax=15; x=6 m <-pbinom(rep(0:x, each = nmax-nmin+1), rep(nmin:nmax,x), prob) dim(m) <- c(nmax-nmin+1,x+1) m <- t(m) colnames(m) <- format(nmin:nmax) rownames(m) <- format(0:x) outHTML(rhtml, m, title="x\n", format="f", digits=4) </R>

<R output="display" iframe="width:400px;height:400px"> pdf(rpdf, width=5, height=5) n <- 10 prob <- 0.2 x <- seq(0, n, 1) p <- dbinom(x, n, prob) param <- list(n, prob) main <- c("Binomialverteilung - Wahrscheinlichkeitsfunktion", paste (c("Stichprobenumfang n", "Wahrscheinlichkeit p"), param, sep="=")) plot(x,p, type="h", main=main) </R>

<R>1:20</R>

$\int _{-N}^{N}e^{x}\,dx$

hola [1]

1. Shaner NC, Campbell RE, Steinbach PA, Giepmans BN, Palmer AE, and Tsien RY. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol. 2004 Dec;22(12):1567-72. DOI:10.1038/nbt1037 |
2. Ubhayasekera W, Muñoz IG, Vasella A, Ståhlberg J, and Mowbray SL. Structures of Phanerochaete chrysosporium Cel7D in complex with product and inhibitors. FEBS J. 2005 Apr;272(8):1952-64. DOI:10.1111/j.1742-4658.2005.04625.x |

3. Casajuana J, Aragonès R, Ariza F. Significado clínico de un PSA elevado FMC 2004;11(10) 604-13.

4. Etzioni RD, Ankerst DP, Weiss NS, Inoue LY, and Thompson IM. Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. J Natl Cancer Inst. 2007 Oct 17;99(20):1510-5. DOI:10.1093/jnci/djm171 |
5. Ilic D, O'Connor D, Green S, and Wilt T. Screening for prostate cancer. Cochrane Database Syst Rev. 2006 Jul 19(3):CD004720. DOI:10.1002/14651858.CD004720.pub2 |
6. Boyd SD and Narayan P. Management of benign prostatic hyperplasia. West J Med. 1994 Feb;160(2):165-6.
7. Hoogendam A, Buntinx F, and de Vet HC. The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis. Fam Pract. 1999 Dec;16(6):621-6. DOI:10.1093/fampra/16.6.621 |
8. Bereczky Z, Bolus M, Chetty P, du Toit W, Enslin J, Haffejee M, Heyns C, Hyams D, Kirstein D, Mackenzie M, Mamine A, Mutambirwa S, Niemand B, Opperman C, Pontin A, Reif S, Sauer F, Segone A, Smart D, Steenkamp P, Stellmacher G, van Wijk F, Wentzel S, and South African Urological Association. Management of benign prostatic hyperplasia - South African Urological Association Guideline. S Afr Med J. 2006 Dec;96(12 Pt 3):1275-9.
9. Rosenberg MT, Staskin DR, Kaplan SA, MacDiarmid SA, Newman DK, and Ohl DA. A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting. Int J Clin Pract. 2007 Sep;61(9):1535-46. DOI:10.1111/j.1742-1241.2007.01491.x |
10. Algaba F, Trias I, and Arce Y. Natural history of prostatic carcinoma: the pathologist's perspective. Recent Results Cancer Res. 2007;175:9-24. DOI:10.1007/978-3-540-40901-4_2 |
11. Okotie OT, Roehl KA, Han M, Loeb S, Gashti SN, and Catalona WJ. Characteristics of prostate cancer detected by digital rectal examination only. Urology. 2007 Dec;70(6):1117-20. DOI:10.1016/j.urology.2007.07.019 |
12. Webber R. Benign prostatic hyperplasia. Clin Evid. 2006 Jun(15):1213-26.
13. Wilt T. Prostate cancer (non-metastatic). Clin Evid. 2003 Dec(10):1023-38.
14. Marzo Castillejo M, Cierco Peguera P, and Bonfill Cosp X. [Prostate cancer screening]. Aten Primaria. 2001 Oct 31;28(7):468-71. DOI:10.1016/s0212-6567(01)70423-4 |
15. Roobol MJ, Kranse R, de Koning HJ, and Schröder FH. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Urology. 2004 Feb;63(2):309-13; discussion 313-5. DOI:10.1016/j.urology.2003.09.083 |
16. Yamamoto T, Ito K, Ohi M, Kubota Y, Suzuki K, Fukabori Y, Kurokawa K, and Yamanaka H. Diagnostic significance of digital rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 NG/ML or less. Urology. 2001 Dec;58(6):994-8. DOI:10.1016/s0090-4295(01)01409-1 |
17. Ilic D and Green S. Screening for prostate cancer in younger men. BMJ. 2007 Dec 1;335(7630):1105-6. DOI:10.1136/bmj.39385.491424.80 |
18. Lin KW and Duane MR. Are some screening tests doing more harm than good?. Am Fam Physician. 2007 Aug 1;76(3):351-2.
19. Irwig L, McCaffery K, Salkeld G, and Bossuyt P. Informed choice for screening: implications for evaluation. BMJ. 2006 May 13;332(7550):1148-50. DOI:10.1136/bmj.332.7550.1148 |
20. Edwards A, Unigwe S, Elwyn G, and Hood K. Effects of communicating individual risks in screening programmes: Cochrane systematic review. BMJ. 2003 Sep 27;327(7417):703-9. DOI:10.1136/bmj.327.7417.703 |
21. U.S. Preventive Services Task Force. Screening for prostate cancer: recommendations and rationale. Am Fam Physician. 2003 Feb 15;67(4):787-92.
22. Sackett DL. The arrogance of preventive medicine. CMAJ. 2002 Aug 20;167(4):363-4.
23. Welch HG. Right and wrong reasons to be screened. Ann Intern Med. 2004 May 4;140(9):754-5. DOI:10.7326/0003-4819-140-9-200405040-00016 |
24. Kort SA, Martens F, Vanpoucke H, van Duijnhoven HL, and Blankenstein MA. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation. Clin Chem. 2006 Aug;52(8):1568-74. DOI:10.1373/clinchem.2006.069039 |
25. Baade PD, Coory MD, and Aitken JF. International trends in prostate-cancer mortality: the decrease is continuing and spreading. Cancer Causes Control. 2004 Apr;15(3):237-41. DOI:10.1023/B:CACO.0000024212.66334.26 |
26. Walsh PC, DeWeese TL, and Eisenberger MA. Clinical practice. Localized prostate cancer. N Engl J Med. 2007 Dec 27;357(26):2696-705. DOI:10.1056/NEJMcp0706784 |
27. Rao AR, Motiwala HG, and Karim OM. The discovery of prostate-specific antigen. BJU Int. 2008 Jan;101(1):5-10. DOI:10.1111/j.1464-410X.2007.07138.x |
28. Gonzalgo ML and Carter HB. Update on PSA testing. J Natl Compr Canc Netw. 2007 Aug;5(7):737-42. DOI:10.6004/jnccn.2007.0065 |
29. Djavan B, Rocco B, Stangelberger A, De Cobelli O, and Marberger M. Is the era of prostate-specific antigen over?. BJU Int. 2007 Jul;100 Suppl 2:8-10. DOI:10.1111/j.1464-410X.2007.06944.x |
30. Thompson IM and Ankerst DP. Prostate-specific antigen in the early detection of prostate cancer. CMAJ. 2007 Jun 19;176(13):1853-8. DOI:10.1503/cmaj.060955 |
31. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen CM, and AUA Prostate Cancer Clinical Guideline Update Panel. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007 Jun;177(6):2106-31. DOI:10.1016/j.juro.2007.03.003 |
32. Frydenberg M and Wijesinha S. Diagnosing prostate cancer - what GPs need to know. Aust Fam Physician. 2007 May;36(5):345-7.
33. Warren KS and McFarlane JP. Is routine digital rectal examination required for the followup of prostate cancer?. J Urol. 2007 Jul;178(1):115-9. DOI:10.1016/j.juro.2007.03.010 |
34. Stephan C, Cammann H, Meyer HA, Lein M, and Jung K. PSA and new biomarkers within multivariate models to improve early detection of prostate cancer. Cancer Lett. 2007 Apr 28;249(1):18-29. DOI:10.1016/j.canlet.2006.12.031 |
35. Walczak JR and Carducci MA. Prostate cancer: a practical approach to current management of recurrent disease. Mayo Clin Proc. 2007 Feb;82(2):243-9. DOI:10.4065/82.2.243 |
36. Llorente C, de la Morena JM, and Ardura MA. [PSA doubling time as a new diagnostic and prognostic method for prostate cancer]. Arch Esp Urol. 2006 Dec;59(10):1083-7. DOI:10.4321/s0004-06142006001000015 |
37. Loeb S and Catalona WJ. Prostate-specific antigen in clinical practice. Cancer Lett. 2007 Apr 28;249(1):30-9. DOI:10.1016/j.canlet.2006.12.022 |
38. Williams SA, Singh P, Isaacs JT, and Denmeade SR. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer?. Prostate. 2007 Feb 15;67(3):312-29. DOI:10.1002/pros.20531 |
39. Kenny LM, Ngan S, and Waxman J. 'Time, gentlemen, please' for watchful waiting in prostate cancer?. BJU Int. 2007 Aug;100(2):244-6. DOI:10.1111/j.1464-410X.2007.07063.x |
40. Hirsh I, Kaploun A, Faris G, Appel B, Shneider I, Stein A, and Pizov R. Tramadol improves patients' tolerance of transrectal ultrasound-guided prostate biopsy. Urology. 2007 Mar;69(3):491-4. DOI:10.1016/j.urology.2006.10.035 |
41. Mallick S, Braud F, Fofana M, Humbert M, Clervil M, and Blanchet P. Which anaesthesia should be recommended for prostate biopsy?. West Indian Med J. 2005 Mar;54(2):135-8. DOI:10.1590/s0043-31442005000200010 |
42. Davison BJ, Parker PA, and Goldenberg SL. Patients' preferences for communicating a prostate cancer diagnosis and participating in medical decision-making. BJU Int. 2004 Jan;93(1):47-51. DOI:10.1111/j.1464-410x.2004.04553.x |
43. Schover LR, Fouladi RT, Warneke CL, Neese L, Klein EA, Zippe C, and Kupelian PA. Defining sexual outcomes after treatment for localized prostate carcinoma. Cancer. 2002 Oct 15;95(8):1773-85. DOI:10.1002/cncr.10848 |

44. Guidance for ...Outcomes in Urological The Research Evidence NICE

45. Pepe P, Panella P, D'Arrigo L, Savoca F, Pennisi M, and Aragona F. Should men with serum prostate-specific antigen < or =4 ng/ml and normal digital rectal examination undergo a prostate biopsy? A literature review. Oncology. 2006;70(2):81-9. DOI:10.1159/000092583 |
46. Hammerer PG, Kattan MW, Mottet N, and Prayer-Galetti T. Using prostate-specific antigen screening and nomograms to assess risk and predict outcomes in the management of prostate cancer. BJU Int. 2006 Jul;98(1):11-9. DOI:10.1111/j.1464-410X.2006.06177.x |
47. Kattan MW and Scardino PT. Prediction of progression: nomograms of clinical utility. Clin Prostate Cancer. 2002 Sep;1(2):90-6. DOI:10.3816/cgc.2002.n.010 |
48. Mistry K and Cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract. 2003 Mar-Apr;16(2):95-101. DOI:10.3122/jabfm.16.2.95 |
49. Hoffman RM, Clanon DL, Chavez M, and Peirce JC. Using multiple cutpoints for the free-to-total prostate specific antigen ratio improves the accuracy of prostate cancer detection. Prostate. 2002 Jul 1;52(2):150-8. DOI:10.1002/pros.10111 |
50. Hoffman RM, Clanon DL, Littenberg B, Frank JJ, and Peirce JC. Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels. J Gen Intern Med. 2000 Oct;15(10):739-48. DOI:10.1046/j.1525-1497.2000.90907.x |
51. Lee R, Localio AR, Armstrong K, Malkowicz SB, Schwartz JS, and Free PSA Study Group. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology. 2006 Apr;67(4):762-8. DOI:10.1016/j.urology.2005.10.052 |
52. Erol H, Beder N, Calişkan T, Dündar M, Unsal A, and Culhaci N. Can the effect of antibiotherapy and anti-inflammatory therapy on serum PSA levels discriminate between benign and malign prostatic pathologies?. Urol Int. 2006;76(1):20-6. DOI:10.1159/000089730 |

1. 2006upur pmid=16504254
2. cocaid pmid=12804407
3. 2006ijcp pmid=17109668
4. tramf tacto rectal amf
5. cks hbp